Sofosbuvir is manufactured by Gilead and is used to treat HCV. ## Compulsory licenses Compulsory licenses have been issued for Sofosbuvir in the following instance: ### Malaysia issued on September 01, 2017 [[Malaysia]]'s provisions on compulsory licences can be in the Patents Act 1983 (Act 291). There are two main grounds to obtain a compulsory licence (all under Section 49 Patents Act 1983): 1. Lack or insufficiency of exploitation After 3 years from grant or 4 years from filing (whichever later), if the patented invention is: - not being worked in Malaysia without legitimate reason; or - worked but does not meet demand in Malaysia without legitimate reason. 2. Special cases (at any time after grant) - If the patented products are sold at unreasonably high prices in Malaysia; or - For pharmaceutical production in Malaysia for export to an eligible importing country facing a public-health problem. The Act also separately provides for Government use (“rights of Government”, Section 84) in the public interest, national emergency, or to remedy anti-competitive practices. More information can be found [here](https://www.myipo.gov.my/wp-content/uploads/2025/02/LAMPIRAN-D37-Patents-Act-1983-Act-291-As-at-30-June-2023-Online-version-of-updated.pdf ). ## Other products issued by the same manufacturer [[Sofosbuvir]] [[Remdesivir]] ## Other products for the same disease [[HCV medicines]] [[DAAs]]